{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Steroid-Refractory+Acute+Graft+Versus+Host+Disease&page=2",
    "query": {
      "condition": "Steroid-Refractory Acute Graft Versus Host Disease",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Steroid-Refractory+Acute+Graft+Versus+Host+Disease&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T07:22:20.645Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02694770",
      "title": "A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Neihulizumab Treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conventional Treatment",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AbGenomics B.V Taiwan Branch",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-07",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2016-04-25",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02694770"
    },
    {
      "nct_id": "NCT03147742",
      "title": "An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Graft-versus-host Disease (GVHD)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03147742"
    },
    {
      "nct_id": "NCT01596218",
      "title": "Brentuximab Vedotin for Steroid Refractory GvHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft vs. Host Disease"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2012-07",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01596218"
    },
    {
      "nct_id": "NCT05333029",
      "title": "Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Allogeneic mesenchymal stromal cells (MSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Extracorporeal photopheresis (ECP)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Molly Gallogly",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-10-01",
      "completion_date": "2025-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05333029"
    },
    {
      "nct_id": "NCT03327857",
      "title": "Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Steroid-refractory Acute Graft-versus-Host Disease",
        "Treatment-refractory Acute Graft-versus-Host Disease"
      ],
      "interventions": [
        {
          "name": "Neihulizumab (ALTB-168)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AltruBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2018-05-31",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-01-19",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Los Angeles, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03327857"
    },
    {
      "nct_id": "NCT02524847",
      "title": "Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Steroid Refractory Acute Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Methoxsalen",
          "type": "DRUG"
        },
        {
          "name": "Extracorporeal Photopheresis (ECP)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Therakos, Inc., a Mallinckrodt Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 29,
      "start_date": "2016-01-20",
      "completion_date": "2019-07-16",
      "has_results": true,
      "last_update_posted_date": "2020-09-11",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02524847"
    },
    {
      "nct_id": "NCT00038792",
      "title": "Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Recombinant Human Keratinocyte Growth Factor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 7,
      "start_date": "2000-10",
      "completion_date": "2003-01",
      "has_results": false,
      "last_update_posted_date": "2012-08-02",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038792"
    },
    {
      "nct_id": "NCT02993783",
      "title": "A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Vedolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2017-04-28",
      "completion_date": "2018-05-09",
      "has_results": true,
      "last_update_posted_date": "2019-05-24",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri • Lake Success, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02993783"
    },
    {
      "nct_id": "NCT01485055",
      "title": "Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Steroid Refractory GVHD",
        "Acute GVH Disease"
      ],
      "interventions": [
        {
          "name": "Infliximab and Basiliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "6 Months to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2011-12",
      "completion_date": "2016-09-26",
      "has_results": true,
      "last_update_posted_date": "2019-04-05",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 3,
      "location_summary": "Gainesville, Florida • Columbus, Ohio • San Antonio, Texas",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01485055"
    },
    {
      "nct_id": "NCT00366145",
      "title": "Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Prochymal®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care for GVHD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mesoblast, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "6 Months to 70 Years"
      },
      "enrollment_count": 260,
      "start_date": "2006-08-17",
      "completion_date": "2009-05-28",
      "has_results": false,
      "last_update_posted_date": "2022-02-10",
      "last_synced_at": "2026-06-11T07:22:20.645Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00366145"
    }
  ]
}